Sickle Cell Disease Therapies
Jan 03, 2025
7 Sickle Cell Disease Therapies to Keep an Eye on Post-Pfizer’s OXBRYTA Withdrawal
In September 2024, Pfizer voluntarily withdrew all lots of OXBRYTA for the treatment of SCD in all markets where it was approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanding access programs worldwide. The decision is based on the totality of clinical data, which now indicates tha...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
